Literature DB >> 6843038

Hypophosphatemia induced by intravenous administration of Saccharated iron oxide.

M Okada, K Imamura, M Iida, T Fuchigami, T Omae.   

Abstract

Forty milligrams saccharated iron oxide was given intravenously, daily, to nine iron-deficient patients with moderate to severe anemia. During the 14-42 days of treatment, levels of serum inorganic phosphorus (Pi) decreased significantly and in a stepwise manner (before vs 1 week, P less than 0.005; 1 week vs 2 weeks, P less than 0.01). Seven of the nine patients became hypophosphatemic within 2 weeks and the other two within 4 weeks. In parallel with the decline in serum Pi, the phosphate clearance increased and tubular reabsorption of phosphate decreased. Reversion to normal levels was delayed in patients treated for the longer period.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6843038     DOI: 10.1007/bf01496662

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  13 in total

1.  Column chromatography of human serum parathyroid immunoreactive peptides.

Authors:  A W Lindall; E T Wong
Journal:  Proc Soc Exp Biol Med       Date:  1975-03

2.  CALCIUM, PHOSPHORUS AND URIC ACID CLEARANCES AFTER INTRAVENOUS ADMINISTRATION OF CHLOROTHIAZIDE.

Authors:  C G DUARTE; J H BLAND
Journal:  Metabolism       Date:  1965-03       Impact factor: 8.694

Review 3.  Effect of phosphorus depletion on the renal transport of phosphate.

Authors:  T H Steele
Journal:  Adv Exp Med Biol       Date:  1978       Impact factor: 2.622

Review 4.  Hypophosphatemia.

Authors:  F T Fitzgerald
Journal:  Adv Intern Med       Date:  1978

5.  Effect of elevated dietary levels of iron on iron store in liver, some blood constituents and phosphorus deficiency in young swine.

Authors:  K Furugouri
Journal:  J Anim Sci       Date:  1972-04       Impact factor: 3.159

6.  Enhanced postglucose hypophosphatemia during starvation therapy of obesity.

Authors:  D G Corredor; G Sabeh; L V Mendelsohn; R E Wasserman; J H Sunder; T S Danowski
Journal:  Metabolism       Date:  1969-09       Impact factor: 8.694

7.  Effects of chlorothiazide and amipramizide (MK 870) on the renal excretion of calcium, phosphate and magnesium.

Authors:  C G Duarte
Journal:  Metabolism       Date:  1968-05       Impact factor: 8.694

8.  Adverse effects of aluminum-containing antacids on mineral metabolism.

Authors:  H Spencer; M Lender
Journal:  Gastroenterology       Date:  1979-03       Impact factor: 22.682

9.  Rapid fall of serum phosphorus secondary to antacid therapy.

Authors:  H M Shields
Journal:  Gastroenterology       Date:  1978-12       Impact factor: 22.682

10.  Association of hypokalaemia and hypophosphataemia.

Authors:  D C Anderson; T J Peters; W K Stewart
Journal:  Br Med J       Date:  1969-11-15
View more
  13 in total

1.  Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient.

Authors:  Y C Fierz; R Kenmeni; A Gonthier; F Lier; F Pralong; P Coti Bertrand
Journal:  Eur J Clin Nutr       Date:  2014-02-26       Impact factor: 4.016

Review 2.  Next-generation phosphate binders: focus on iron-based binders.

Authors:  Dimitra Nastou; Beatriz Fernández-Fernández; Usama Elewa; Liliana González-Espinoza; Emilio González-Parra; Maria D Sanchez-Niño; Alberto Ortiz
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients.

Authors:  Serpil Muge Deger; Yasemin Erten; Ozge Tugce Pasaoglu; Ulver Boztepe Derici; Kadriye Altok Reis; Kursad Onec; Hatice Pasaoglu
Journal:  Clin Exp Nephrol       Date:  2012-11-20       Impact factor: 2.801

Review 4.  Safety of new phosphate binders for chronic renal failure.

Authors:  Mahmoud Loghman-Adham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  New Therapies for Hypophosphatemia-Related to FGF23 Excess.

Authors:  Diana Athonvarangkul; Karl L Insogna
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

Review 6.  Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.

Authors:  John A Glaspy; Myles Wolf; William E Strauss
Journal:  Adv Ther       Date:  2021-05-30       Impact factor: 3.845

7.  Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis.

Authors:  Toru Sanai; Takashi Ono; Toma Fukumitsu
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271

8.  A Case of an Insufficiency Fracture of the Medial Proximal Tibia Secondary to Osteomalacia Associated with Long-Term Saccharated Ferric Oxide Administration.

Authors:  Daichi Ishimaru; Hiroshi Sumi
Journal:  Case Rep Orthop       Date:  2017-07-04

9.  A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).

Authors:  Walter Reinisch; Michael Staun; Rakesh K Tandon; Istvan Altorjay; Andrew V Thillainayagam; Cornelia Gratzer; Sandeep Nijhawan; Lars L Thomsen
Journal:  Am J Gastroenterol       Date:  2013-10-22       Impact factor: 10.864

Review 10.  Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia.

Authors:  Philip A Kalra; Sunil Bhandari
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.